UMIN-CTR Clinical Trial

Recruitment status Completed
Unique ID issued by UMIN UMIN000039671
Receipt No. R000045187
Scientific Title A study for the effect of intake of ONO-SR/AST-SOYPC on cognitive functions
Date of disclosure of the study information 2021/12/31
Last modified on 2022/07/07 (Ver. 9)

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information
Public title A study for the effect of intake of ONO-SR/AST-SOYPC on cognitive functions
Acronym A study for the effect of intake of ONO-SR/AST-SOYPC on cognitive functions
Scientific Title A study for the effect of intake of ONO-SR/AST-SOYPC on cognitive functions
Scientific Title:Acronym A study for the effect of intake of ONO-SR/AST-SOYPC on cognitive functions
Region
Japan

Condition
Condition Healthy adult
Classification by specialty
Adult
Classification by malignancy Others
Genomic information NO

Objectives
Narrative objectives1 To evaluate the effect on cognitive function of ONO-SR/AST-SOYPC daily intake, for 12 weeks
Basic objectives2 Efficacy
Basic objectives -Others
Trial characteristics_1
Trial characteristics_2
Developmental phase

Assessment
Primary outcomes Tests for cognitive functions
Key secondary outcomes

Base
Study type Interventional

Study design
Basic design Parallel
Randomization Randomized
Randomization unit Individual
Blinding Double blind -all involved are blinded
Control Placebo
Stratification NO
Dynamic allocation
Institution consideration
Blocking
Concealment

Intervention
No. of arms 2
Purpose of intervention Prevention
Type of intervention
Food
Interventions/Control_1 Intake of test food daily intake, for 12 weeks
Interventions/Control_2 Intake of placebo daily intake, for 12 weeks
Interventions/Control_3
Interventions/Control_4
Interventions/Control_5
Interventions/Control_6
Interventions/Control_7
Interventions/Control_8
Interventions/Control_9
Interventions/Control_10

Eligibility
Age-lower limit
60 years-old <=
Age-upper limit
85 years-old >=
Gender Male and Female
Key inclusion criteria (1) Healthy males and females from 60 to 85 years of age
(2) Subjects with self-awareness of forgetfulness or Those who are pointed out that there is forgetfulness
Key exclusion criteria (1) Subjects who constantly use health food richly containing involvement ingredient
(2) Subjects who regularly take drugs or health foods which may affect this study more than once a week
(3) Subjects whose visual acuity is too low to perform test
(4) Subjects whose hearing acuity is too low to perform test
(5) Subjects having a disease of mental disorder, dementia, cranial nerve disease, or cerebrovascular disease.
(6) Subjects with current menopausal disorders
(7) Subjects taking drugs that may affect the results of the study
(8) Subjects having a disease requiring treatment or a history of serious diseases for which medication was required
(9) Subjects having a drug dependence, alcohol dependence requiring treatment or a history of serious alcohol dependence
(10) Subjects suspected of having dementia based on cognitive function tests and physician interviews.
(11) Subjects who may experience irregularities in their lives more than once during the study period due to night shifts, etc.
(12) Subjects who are current smokers or have started smoking cessation within 12 months before the pre-treatment test.
(13) Subjects who have performed the cognitive tests within 12 months prior to the pre-treatment test.
(14) Subjects who donated or transfused 200 mL or 400 mL of whole blood within 3 months before the pre-treatment test.
(15) Subjects who have participated in other clinical study within the last one month prior to the current study or are planned to participate in other clinical study after informed consent for the current study.
(16) Subjects who are judged as unsuitable for the study based on the results of clinical and physical examination on the pre-treatment test.
(17) Subjects at risk of developing allergy in relation to the study.
(18) Subjects who are judged as unsuitable for the study based on the results of lifestyle questionnaire
(19) Subjects judged as unsuitable for the study by the investigator for other reasons.
Target sample size 100

Research contact person
Name of lead principal investigator
1st name Yasunari
Middle name
Last name Noda
Organization ONO PHARMACEUTICAL CO., LTD.
Division name Business Design Department
Zip code 541-8564
Address 8-2, Kyutaromachi 1-chome, Chuo-ku, Osaka
TEL 06-6263-2924
Email ya.noda@ono.co.jp

Public contact
Name of contact person
1st name Takashi
Middle name
Last name Nakagawa
Organization TTC Co., Ltd.
Division name Clinical Research Planning Department
Zip code 150-0021
Address Seibu Shinkin Bank Ebisu Bldg., 1-20-2, Ebisunishi, Shibuya-ku, Tokyo
TEL 03-5459-5329
Homepage URL
Email t.nakagawa@ttc-tokyo.co.jp

Sponsor
Institute TTC Co., Ltd
Institute
Department

Funding Source
Organization Ono Pharmaceutical co.,ltd
Organization
Division
Category of Funding Organization Profit organization
Nationality of Funding Organization

Other related organizations
Co-sponsor
Name of secondary funder(s)

IRB Contact (For public release)
Organization Medical Station Clinic Research Ethics Committee
Address 3-12-8, Takaban, Meguroku, Tokyo
Tel 03-6452-2712
Email t.saito@ttc-smo.jp

Secondary IDs
Secondary IDs NO
Study ID_1
Org. issuing International ID_1
Study ID_2
Org. issuing International ID_2
IND to MHLW

Institutions
Institutions

Other administrative information
Date of disclosure of the study information
2021 Year 12 Month 31 Day

Related information
URL releasing protocol
Publication of results Unpublished

Result
URL related to results and publications
Number of participants that the trial has enrolled 100
Results
Results date posted
Results Delayed
Results Delay Reason
Date of the first journal publication of results
Baseline Characteristics
Participant flow
Adverse events
Outcome measures
Plan to share IPD
IPD sharing Plan description

Progress
Recruitment status Completed
Date of protocol fixation
2020 Year 02 Month 13 Day
Date of IRB
2020 Year 02 Month 13 Day
Anticipated trial start date
2020 Year 03 Month 02 Day
Last follow-up date
2020 Year 12 Month 31 Day
Date of closure to data entry
Date trial data considered complete
Date analysis concluded

Other
Other related information

Management information
Registered date
2020 Year 03 Month 03 Day
Last modified on
2022 Year 07 Month 07 Day


Link to view the page
URL(English) https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000045187